# US 2024/0199562 A1 · Urea derivatives for treating uveal melanoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199562 A1
- Document ID: US20240199562A1
- Status: Published application
- Kind: A1
- Application number: 18/286,569
- Filed: 2022-04-14
- Published: 2024-06-20
- Earliest claimed: 2021-04-14
- Assignees: Centre National De La Recherche Scientifique; Institut National de la Sante et de la Recherche Medicale; Université CôTe D’Azur; Institut Curie
- Applicants: Centre National De La Recherche Scientifique; Institut National De La Santé Et De La Recherche MéDicale; Université Cote D’Azur; Institut Curie
- Inventors: MAEVA DUFIES; GILLES PAGES; CYRIL RONCO; RACHID BENHIDA
- Web page: https://patentgrep.com/patent/US20240199562A1

## CPC

- C07D 277/82: Nitrogen atoms
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/423: condensed with carbocyclic rings
- A61K 31/428: condensed with carbocyclic rings
- A61P 35/00: Antineoplastic agents
- C07D 235/30: Nitrogen atoms not forming part of a nitro radical
- C07D 263/58: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to ureal derivatives of formula (I) and pharmaceutical compositions comprising such derivatives for use in the treatment of uveal melanoma.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method of treating uveal melanoma comprising administering a compound of formula (I), a pharmaceutically acceptable salt thereof, a tautomer thereof, or a composition comprising said compound, pharmaceutically acceptable salt, or tautomer to a subject having uveal melanoma:
in which:
Y is 13 NH—, —S—, or —O—;
R1 is a radical selected from the group consisting of:
a hydrogen atom,
a (C1-C6)alkyloxy group,
a (C1-C6)alkyl group,
a nitro group,
a —NR3R4 group with R3 and R4 are independently a radical selected from the group consisting of:
a hydrogen atom,
a —COR5 with R5 is a (C1-C6)alkyl group, and
a —SO2R6 with R6 is a (C1-C6)alkyl group,
a halogen atom, and
a 3-14 membered ring selected from the group consisting of an aryl, a heteroaryl, a cycloalkyl, and a heterocycloalkyl, said 3-14 membered ring is optionally substituted by a radical selected from the group consisting of a (C1-C6)alkyl group, a (C1-C6)alkyloxy group, a halogen atom, a nitro group, and a carboxyl group;
R2 is a radical selected from the group consisting of:
a hydrogen atom,
a halogen atom,
a (C1-C6)alkyloxy group, and
a (C1-C6)alkyl group;
n is an integer number from 0 to 5.

### Claim 17 (depends on 16)

The method according to claim 16, wherein Y is —S— or —O—.

### Claim 18 (depends on 16)

The method according to claim 16, wherein Ri is a radical selected from the group consisting of:
a hydrogen atom,
an ethoxy group,
a methyl group,
a nitro group,
a —NR3R4 group with R3 and R4 are independently a radical selected from the group consisting of:
a hydrogen atom,
a —COR5 with R5 is a methyl group, and
a —SO2R6 with R6 is a methyl group,
a halogen atom, and
a 3-14 membered ring selected from the group consisting of a thiophenyl, a furanyl, a naphthalenyl, and a pyridinyl, said 3-14 membered ring is optionally substituted by a radical selected from the group consisting of a (C1-C6)alkyl group, a (C1-C6)alkyloxy group, a halogen atom, a nitro group, and a carboxyl group.

### Claim 19 (depends on 16)

The method according to claim 16, wherein R1 is a radical selected from the group consisting of an ethoxy group, a nitro group, and a 3-14 membered ring selected from the group consisting of a thiophenyl, a furanyl, a naphthalenyl, and a pyridinyl, said 3-14 membered ring is optionally substituted by a radical selected from the group consisting of a (C1-C6)alkyl group, a (C1-C6)alkyloxy group, a halogen atom, a nitro group, and a carboxyl group.

### Claim 20 (depends on 16)

The method according to claim 16, wherein n is an integer number from 1 to 3.

### Claim 21 (depends on 16)

The method according to claim 16, wherein n is 1 or 2, and R2 is in meta position.

### Claim 22 (depends on 16)

The method according to claim 16, wherein R2 is a radical selected from the group consisting of:
a hydrogen atom,
a halogen atom,
a methoxy group, and
a methyl group.

### Claim 23 (depends on 16)

The method according to claim 16, wherein said compound is of formula (IA):

### Claim 24 (depends on 16)

The method according to claim 16, wherein said compound is selected from the group consisting of:
1-(1H-benzo[d]imidazol-2-yl)-3-(3-chlorophenyl)urea (MCK109);
1-(1H-benzo[d]imidazol-2-yl)-3-(2-chlorophenyl)urea (MCK110);
1-(benzo[d]oxazol-2-yl)-3-phenylurea (MCK112);
1-(1H-benzo[d]imidazol-2-yl)-3-phenylurea (MCK113);
1-(1H-benzo[d]imidazol-2-yl)-3-(4-chlorophenyl)urea (MCK115);
1-(benzo[d]thiazol-2-yl)-3-phenylurea (MCK126);
1-(benzo[d]thiazol-2-yl)-3-(2-chlorophenyl)urea (MCK127);
1-(benzo[d]thiazol-2-yl)-3-(3-chlorophenyl)urea (MCK128);
1-(benzo[d]thiazol-2-yl)-3-(4-chlorophenyl)urea (MCK129);
1-(benzo[d]thiazol-2-yl)-3-(4-methoxyphenyl)urea (MCK130);
1-(1H-benzo[d]imidazol-2-yl)-3-(4-methoxyphenyl)urea (MCK131);
1-(6-ethoxybenzo[d]thiazol-2-yl)-3-(p-tolyl)urea (MCK132);
1-(6-ethoxybenzo[d]thiazol-2-yl)-3-(o-tolyl)urea (MCK133);
1-(6-ethoxybenzo[d]thiazol-2-yl)-3-(m-tolyl)urea (MCK134);
1-(6-ethoxybenzo[d]thiazol-2-yl)-3-(4-methoxyphenyl)urea (MCK135);
1-(2-chlorophenyl)-3-(6-methylbenzo[d]thiazol-2-yl)urea (MCK136);
1-(3-chlorophenyl)-3-(6-methylbenzo[d]thiazol-2-yl)urea (MCK137);
1-(6-methylbenzo[d]thiazol-2-yl)-3-(m-tolyl)urea (MCK138);
1-(2-chlorophenyl)-3-(6-nitrobenzo[d]thiazol-2-yl)urea (MCK139);
1-(3-chlorophenyl)-3-(6-nitrobenzo[d]thiazol-2-yl)urea (MCK140);
1-(4-bromophenyl)-3-(6-nitrobenzo[d]thiazol-2-yl)urea (MCK147);
1-(6-aminobenzo[d]thiazol-2-yl)-3-(3-chlorophenyl)urea (MCK148);
N-(2-(3-(3-chlorophenyl)ureido)benzo[d]thiazol-6-yl)acetamide (MCK149);
N-(2-(3-(3-chlorophenyl)ureido)benzo[d]thiazol-6-yl)methanesulfonamide (MCK150);
1-(3,5-dichlorophenyl)-3-(6-nitrobenzo[d]thiazol-2-yl)urea (MCK151);
1-(4-methoxyphenyl)-3-(6-nitrobenzo[d]thiazol-2-yl)urea (MCK152);
1-(6-nitrobenzo[d]oxazol-2-yl)-3-(m-tolyl)urea (MCK153);
1-(5-nitrobenzo[d]oxazol-2-yl)-3-phenylurea (MCK154);
1-(6-nitro-1H-benzo[d]thiazol-2-yl)-3-phenylurea (MCK155);
1-(3-chlorophenyl)-3-(6-nitro-1 H-benzo[d]imidazol-2-yl)urea (MCK156);
1-(6-nitro-1H-benzo[d]imidazol-2-yl)-3-phenylurea (MCK157);
1-(3-chlorophenyl)-3-(5-nitrobenzo[d]oxazol-2-yl)urea (MCK158);
1-(6-bromobenzo[d]thiazol-2-yl)-3-(3-chlorophenyl)urea (MCK159);
1-(3-chlorophenyl)-3-(6-nitrobenzo[d]oxazol-2-yl)urea (MCK160);
1 1-(3-chlorophenyl)-3-(6-(thiophen-2-yl)benzo[d]thiazol-2-yl)urea (MCK161);
1-(3-chlorophenyl)-3-(6-(furan-2-yl)benzo[d]thiazol-2-yl)urea (MCK162);
1-(3-chlorophenyl)-3-(6-(thiophen-3-yl)benzo[d]thiazol-2-yl)urea (MCK163);
1-(3-chlorophenyl)-3-(6-(naphthalen-1-yl)benzo[d]thiazol-2-yl)urea (MCK164);
1-(2-bromophenyl)-3-(6-nitrobenzo[d]thiazol-2-yl)urea (MCK165);
1-(3-chlorophenyl)-3-(6-ethoxybenzo[d]thiazol-2-yl)urea (MCK166);
1-(3,5-dichlorophenyl)-3-(6-ethoxybenzo[d]thiazol-2-yl)urea (MCK167);
1-(6-nitrobenzo[d]thiazol-2-yl)-3-(p-tolyl)urea (MCK168);
1-(4-chlorophenyl)-3-(6-nitrobenzo[d]thiazol-2-yl)urea (MCK169);
1-(3-chlorophenyl)-3-(6-(pyridin-2-yl)benzo[d]thiazol-2-yl)urea (MCK172); and
1-(6-nitrobenzo[d]thiazol-2-yl)-3-(o-tolyl)urea (MCK173).

### Claim 25 (depends on 16)

The method according to claim 16, said method comprising administering a pharmaceutical composition to the subject topically, orally, or parenterally.

### Claim 26

A compound, a pharmaceutically acceptable salt or a tautomer thereof, of formula (I):
in which:
Y is —S—, or —O—;
R1 is a radical selected from the group consisting of:
a nitro group, a —NR3R4 group with one of R3 or R4 is H and the other is a —SO2R6 with R6 is a (C1-C6)alkyl group, and
a 3-14 membered ring selected from the group consisting of a thiophenyl, a furanyl, and a naphthalenyl, said 3-14 membered ring is optionally substituted by a radical selected from the group consisting of a (C1-C6)alkyl group, a (C1-C6)alkyloxy group, a halogen atom, a nitro group, and a carboxyl group;
with the proviso that when R1 is a nitro group, then Y is —O—;
R2 is a radical selected from the group consisting of:
a hydrogen atom,
a halogen atom,
a (C1-C6)alkyloxy group, and
a (C1-C6)alkyl group; and
n is an integer number from 0 to 5.

### Claim 27 (depends on 26)

The compound according to claim 26, wherein said compound is selected from the group consisting of:
N-(2-(3-(3-chlorophenyl)ureido)benzo[d]thiazol-6-yl)methanesulfonamide (MCK150);
1-(5-nitrobenzo[d]oxazol-2-yl)-3-phenylurea (MCK154);
1-(3-chlorophenyl)-3-(5-nitrobenzo[d]oxazol-2-yl)urea (MCK158);
1-(3-chlorophenyl)-3-(6-nitrobenzo[d]oxazol-2-yl)urea (MCK160);
1-(3-chlorophenyl)-3-(6-(thiophen-2-yl)benzo[d]thiazol-2-yl)urea (MCK161);
1-(3-chlorophenyl)-3-(6-(furan-2-yl)benzo[d]thiazol-2-yl)urea (MCK162);
1-(3-chlorophenyl)-3-(6-(thiophen-3-yl)benzo[d]thiazol-2-yl)urea (MCK163); and
1-(3-chlorophenyl)-3-(6-(naphthalen-1-yl)benzo[d]thiazol-2-yl)urea (MCK164).

### Claim 28

A compound selected from the group consisting of:
N-(2-(3-(3-chlorophenyl)ureido)benzo[d]thiazol-6-yl)acetamide (MCK149);
N-(2-(3-(3-chlorophenyl)ureido)benzo[d]thiazol-6-yl)methanesulfonamide (MCK150);
1-(5-nitrobenzo[d]oxazol-2-yl)-3-phenylurea (MCK154);
1-(6-nitro-1H-benzo[d]imidazol-2-yl)-3-phenylurea (MCK157);
1-(3-chlorophenyl)-3-(5-nitrobenzo[d]oxazol-2-yl)urea (MCK158);
1-(3-chlorophenyl)-3-(6-nitrobenzo[d]oxazol-2-yl)urea (MCK160);
1-(3-chlorophenyl)-3-(6-(thiophen-2-yl)benzo[d]thiazol-2-yl)urea (MCK161);
1-(3-chlorophenyl)-3-(6-(furan-2-yl)benzo[d]thiazol-2-yl)urea (MCK162);
1-(3-chlorophenyl)-3-(6-(thiophen-3-yl)benzo[d]thiazol-2-yl)urea (MCK163);
1-(3-chlorophenyl)-3-(6-(naphthalen-1-yl)benzo[d]thiazol-2-yl)urea (MCK164);
1-(3,5-dichlorophenyl)-3-(6-ethoxybenzo[d]thiazol-2-yl)urea (MCK167); and
1-(3-chlorophenyl)-3-(6-(pyridin-2-yl)benzo[d]thiazol-2-yl)urea (MCK172).

### Claim 29 (depends on 26)

A pharmaceutical composition comprising a compound according to claim 26 and a pharmaceutically acceptable carrier.

### Claim 30 (depends on 28)

A pharmaceutical composition comprising a compound according to claim 28 and a pharmaceutically acceptable carrier.

### Claim 31 (depends on 26)

A method of treating cancer comprising administering a compound according to claim 26, or a pharmaceutical composition comprising said compound to a subject having cancer.

### Claim 32 (depends on 31)

The method according to claim 31, wherein said compound is selected from the group consisting of:
N-(2-(3-(3-chlorophenyl)ureido)benzo[d]thiazol-6-yl)methanesulfonamide (MCK150);
1-(5-nitrobenzo[d]oxazol-2-yl)-3-phenylurea (MCK154);
1-(3-chlorophenyl)-3-(5-nitrobenzo[d]oxazol-2-yl)urea (MCK158);
1-(3-chlorophenyl)-3-(6-nitrobenzo[d]oxazol-2-yl)urea (MCK160);
1-(3-chlorophenyl)-3-(6-(thiophen-2-yl)benzo[d]thiazol-2-yl)urea (MCK161);
1-(3-chlorophenyl)-3-(6-(furan-2-yl)benzo[d]thiazol-2-yl)urea (MCK162);
1-(3-chlorophenyl)-3-(6-(thiophen-3-yl)benzo[d]thiazol-2-yl)urea (MCK163); and
1-(3-chlorophenyl)-3-(6-(naphthalen-1-yl)benzo[d]thiazol-2-yl)urea (MCK164).

### Claim 33 (depends on 28)

A method of treating cancer comprising administering a compound according to claim 28, or a pharmaceutical composition comprising said compound to a subject having cancer.
